Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Functional Pdgfra fibroblast heterogeneity in normal and fibrotic mouse lung
Carol S. Trempus, … , Anne K. Perl, Stavros Garantziotis
Carol S. Trempus, … , Anne K. Perl, Stavros Garantziotis
Published October 12, 2023
Citation Information: JCI Insight. 2023;8(22):e164380. https://doi.org/10.1172/jci.insight.164380.
View: Text | PDF
Research Article Pulmonology

Functional Pdgfra fibroblast heterogeneity in normal and fibrotic mouse lung

  • Text
  • PDF
Abstract

Aberrant fibroblast function plays a key role in the pathogenesis of idiopathic pulmonary fibrosis, a devastating disease of unrelenting extracellular matrix deposition in response to lung injury. Platelet-derived growth factor α–positive (Pdgfra+) lipofibroblasts (LipoFBs) are essential for lung injury response and maintenance of a functional alveolar stem cell niche. Little is known about the effects of lung injury on LipoFB function. Here, we used single-cell RNA-Seq (scRNA-Seq) technology and PdgfraGFP lineage tracing to generate a transcriptomic profile of Pdgfra+ fibroblasts in normal and injured mouse lungs 14 days after bleomycin exposure, generating 11 unique transcriptomic clusters that segregated according to treatment. While normal and injured LipoFBs shared a common gene signature, injured LipoFBs acquired fibrogenic pathway activity with an attenuation of lipogenic pathways. In a 3D organoid model, injured Pdgfra+ fibroblast–supported organoids were morphologically distinct from those cultured with normal fibroblasts, and scRNA-Seq analysis suggested distinct transcriptomic changes in alveolar epithelia supported by injured Pdgfra+ fibroblasts. In summary, while LipoFBs in injured lung have not migrated from their niche and retain their lipogenic identity, they acquire a potentially reversible fibrogenic profile, which may alter the kinetics of epithelial regeneration and potentially contribute to dysregulated repair, leading to fibrosis.

Authors

Carol S. Trempus, Brian N. Papas, Maria I. Sifre, Carl D. Bortner, Erica Scappini, Charles J. Tucker, Xin Xu, Katina L. Johnson, Leesa J. Deterding, Jason G. Williams, Dylan J. Johnson, Jian-Liang Li, Deloris Sutton, Charan Ganta, Debabrata Mahapatra, Muhammad Arif, Abhishek Basu, Lenny Pommerolle, Resat Cinar, Anne K. Perl, Stavros Garantziotis

×

Figure 8

Correlation of normal and fibrogenic fibroblast marker genes with pulmonary fibrosis and disease progression.

Options: View larger image (or click on image) Download as PowerPoint
Correlation of normal and fibrogenic fibroblast marker genes with pulmon...
(A) Normalized TPM expression of normal lipofibroblast (cluster 0), injured lipofibroblast (cluster 6), and myofibroblast (cluster 9) markers in bleomycin-induced pulmonary fibrosis bulk lung transcriptomic data from the Mouse Lung Fibrosis Atlas. (B) Normal lipofibroblast and myofibroblast marker genes in the gene coexpression network from the Mouse Lung Fibrosis Atlas.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts